Tremelimumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tremelimumab
Accession Number
DB11771
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Ticilimumab
External IDs
CP-675206
Categories
UNII
QEN1X95CIX
CAS number
745013-59-6

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Tremelimumab.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Tremelimumab.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tremelimumab.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Tremelimumab.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tremelimumab.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tremelimumab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tremelimumab.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Tremelimumab.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Tremelimumab.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Tremelimumab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Tremelimumab.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Tremelimumab.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tremelimumab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tremelimumab.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Tremelimumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tremelimumab.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Tremelimumab.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tremelimumab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tremelimumab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Tremelimumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Tremelimumab.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Tremelimumab.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Tremelimumab.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Tremelimumab.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Tremelimumab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tremelimumab.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Tremelimumab.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Tremelimumab.Experimental
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tremelimumab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tremelimumab.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Tremelimumab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Tremelimumab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Tremelimumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Tremelimumab.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Tremelimumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Tremelimumab.Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Tremelimumab.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Tremelimumab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Tremelimumab.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911239

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentCancer, Breast / Hormone Receptor Positive, HER2 Negative Breast Cancer1
0RecruitingTreatmentMalignant Neoplasms of Oropharynx1
0RecruitingTreatmentMalignant Neoplasms of Urinary Tract1
0RecruitingTreatmentRenal Cancers1
1Active Not RecruitingOtherSolid Malignancies1
1Active Not RecruitingTreatmentAdvanced Solid Tumors3
1Active Not RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Cervical Cancers / Colorectal Cancers / Renal Cell Adenocarcinoma1
1Active Not RecruitingTreatmentHepatocellular,Carcinoma / Liver Cancer / Liver Cell Caricinoma / Neoplasms, Hepatic1
1Active Not RecruitingTreatmentMetastatic Melanoma1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentRecurrent Melanoma / Stage IV Melanoma1
1CompletedOtherPart A and B: Advanced Solid Malignancies / Part C: Malignant Mesothelioma1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMelanoma1
1CompletedTreatmentRenal Cell Adenocarcinoma1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1Not Yet RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1Not Yet RecruitingTreatmentMetastatic Endometrial cancer / Metastatic Vaginal Cancer / Metastatic Vulvar Cancer / Ovarian Cancer Metastatic / Recurrent Cervical Carcinoma / Recurrent Endometrial Cancer / Recurrent Gynecological Cancer / Recurrent Ovarian Carcinoma / Recurrent Vaginal Cancer / Recurrent Vulvar Cancer / Recurrent, IV-B Cervical cancer1
1RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Squamous Cell of Head and Neck / Esophagogastric Junction Neoplasms / Fallopian Tube Neoplasms / Neoplasms, Ovarian / Pancreatic Ductal Carcinoma / Small Cell Lung Carcinoma / Squamous Cell Carcinoma of Esophagus / Stomach Neoplasms / Triple Negative Breast Neoplasms1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Biliary Tract Cancer / Cancer, Breast / Colorectal Cancers / Gastrooesophageal Cancer / Head and Neck Carcinoma / Lung Cancers / Melanoma1
1RecruitingTreatmentCancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1RecruitingTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Melanoma / Metastatic1
1RecruitingTreatmentColorectal Cancers / Hepatic Metastases1
1RecruitingTreatmentExtensive-Stage Small Cell Lung Cancer1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentMetastatic Carcinoma in the Liver / MLH1 Gene Mutation / MSH6 Gene Mutation / PMS2 Gene Mutation / Stage IV Colorectal Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentMetastatic Anaplastic Thyroid Cancer1
1RecruitingTreatmentMyelodysplastic Syndrome1
1RecruitingTreatmentProstatic Neoplasms1
1RecruitingTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
1RecruitingTreatmentSelected Advanced Solid Tumors1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentMelanoma1
1TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1TerminatedTreatmentProstate Cancer1
1WithdrawnTreatmentBladder Cancers1
1, 2Active Not RecruitingTreatmentAdvanced Malignancy1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2CompletedTreatmentAdvanced Solid Tumors / Aggressive B-cell Lymphomas1
1, 2Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Metastatic squamous cell carcinoma1
1, 2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentAbdominal wall neoplasm / Cancer, Ovarian / Fallopian Tube Cancer1
1, 2RecruitingTreatmentAdvanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck / Metastatic Squamous Cell Carcinoma of the Head and Neck1
1, 2RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Ovarian Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1, 2RecruitingTreatmentBladder Cancers / Cancer, Breast / Cutaneous T-Cell Lymphoma (CTCL) / Head and Neck Squamous Cell Carcinoma (HNSCC) / Melanoma / Neuroendocrine Carcinoma of the Skin / Prostate Cancer / Renal Cancers / Sarcomas1
1, 2RecruitingTreatmentCarcinoma, Colorectal / Colorectal Adenocarcinoma / Colorectal Cancers / Metastatic Disease / Microsatellite-Stable (MSS) Tumor / Neoplasms, Colorectal / Refractory Cancer1
1, 2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Renal Papillary Cell Carcinoma1
1, 2RecruitingTreatmentEsophageal Cancers1
1, 2RecruitingTreatmentGastric or Gastroesophageal Junction Adenocarcinoma1
1, 2RecruitingTreatmentHapatocellular Carcinoma / Liver Cancer / Liver Cell Caricinoma / Neoplasms, Hepatic1
1, 2RecruitingTreatmentHead and Neck Carcinoma1
1, 2RecruitingTreatmentMalignant Melanoma1
1, 2RecruitingTreatmentMetastatic Colorectal Cancers1
1, 2RecruitingTreatmentPrimary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentMelanoma / Neoplasms / Neoplasms, Colorectal / Patients Who Have/Have Had Melanoma and Other Tumors / Prostatic Neoplasms / Renal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentPancreatic Ductal Adenocarcinoma / Triple-Negative Breast Cancer (TNBC) / UBC (Urothelial Bladder Cancer)/ TNBC (Triple-negative Breast Cancer)/ PDAC (Pancreatic Ductal Adenocarcinoma) / Urothelial Bladder Cancer1
2Active Not RecruitingTreatmentRecurrent/Metastatic Squamous Cell Carcinoma of Head & Neck1
2Active Not RecruitingTreatmentUnresectable Pleural or Peritoneal Malignant Mesothelioma1
2CompletedOtherMelanoma1
2CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
2CompletedTreatmentNeoplasms, Colorectal1
2CompletedTreatmentRefractory Melanoma1
2CompletedTreatmentUveal Melanoma1
2Not Yet RecruitingTreatmentColorectal Cancers / Hepatic Metastases1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentMetastatic Adult Soft Tissue Sarcoma / Recurrent Adult Soft Tissue Sarcoma1
2Not Yet RecruitingTreatmentMuscle-invasive Bladder Cancer1
2Not Yet RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer / Squamous Non-Small Cell Lung Cancer1
2RecruitingOtherMesothelioma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas1
2RecruitingTreatmentAdvanced Rare Tumours1
2RecruitingTreatmentAdvanced and/or Metastatic Sarcoma1
2RecruitingTreatmentBiliary Tract Neoplasms1
2RecruitingTreatmentCancer, Breast / Estrogen Receptor Positive Tumor / Hormone Antagonist / Menopause1
2RecruitingTreatmentCancers / Rare Diseases1
2RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2RecruitingTreatmentDurvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma / Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC1
2RecruitingTreatmentDysgerminoma / Germ Cell Tumors / Germinomatous Germ Cell Tumor / Nonseminomatous Germ Cell Tumor / Pineal Germ Cell Tumor / Seminoma1
2RecruitingTreatmentEndometrial Cancers / Endometrial Carcinoma / Endometrial Carcinoma, Recurrent / Endometrial Carcinosarcoma / Recurrent Endometrial Cancer1
2RecruitingTreatmentGerm Cell Tumors1
2RecruitingTreatmentHepatocellular,Carcinoma1
2RecruitingTreatmentLung Cancer Metastatic1
2RecruitingTreatmentMalignant Gliomas / Recurrent Glioblastoma1
2RecruitingTreatmentMalignant Neoplasm of Female Genital Organ1
2RecruitingTreatmentMesothelioma1
2RecruitingTreatmentMetastatic Colorectal Cancers2
2RecruitingTreatmentMicrosatellite Stable / Recurrent Colorectal Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Colorectal Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
2RecruitingTreatmentNeuroendocrine Neoplasm of Lung / Neuroendocrine Tumors1
2RecruitingTreatmentPeritoneal Mesotheliomas / Pleural Mesotheliomas1
2RecruitingTreatmentPlatinum Refractory Extensive-Stage Small Cell Lung Carcinoma1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentRecurrent Small Cell Lung Carcinoma1
2SuspendedTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
2Unknown StatusTreatmentMesothelioma, Malignant2
2WithdrawnTreatmentBladder Cancers1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV)1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v71
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3CompletedTreatmentMelanoma1
3No Longer AvailableNot AvailableAdvanced Unresectable Melanoma1
3Not Yet RecruitingTreatmentRenal Cell Adenocarcinoma1
3RecruitingTreatmentBladder Cancers / Urothelial Cancer1
3RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC1
3RecruitingTreatmentSmall Cell Lung Carcinoma Extensive Disease1
Not AvailableActive Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
Not AvailableTerminatedNot AvailableMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:46 / Updated on November 06, 2017 06:46